About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

RECRUITINGPhase 4

Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study

Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study (NuPOWER)

NCT05935358•Octapharma

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Severe Hemophilia A

Interventions

Nuwiq

Locations

18

United States

Locations (18)

UT Southwestern Medical Center

Dallas, Texas, United States

University Hospital Centre Zagreb

Zagreb, Croatia

Helsinki University Hospital

Helsinki, Finland

CHU de Nantes Hôtel-Dieu

Nantes, France

CHRU de Tours

Tours, France

Vivantes Klinikum im Friedrichshein (KFH)

Berlin, Germany

Key Dates

Start Date

November 28, 2023

Primary Completion Date

August 1, 2026

Completion Date

August 1, 2026

Last Updated

October 24, 2025

Related Studies

RECRUITINGPhase 1

A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.

NCT06703606

Severe Hemophilia A

Enrolling By InvitationNA

Palliative Care Needs of Children With Rare Diseases and Their Families

NCT06938542

Trisomy 13 SyndromeArthrogryposis Congenita Multiplex With Intestinal Atresia+17 more

Not Yet Recruiting

Post Approval Observational Study to Learn More About How Safe Octocog Alfa is and How Well it Works in Patients With Severe Hemophilia A in India

NCT07446010

Severe Hemophilia A

Not Yet RecruitingPhase 3

Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A

NCT06136507

Severe Hemophilia A

COMPLETEDPhase 4

Clinical Outcomes of Low Dose PK-guided EHL FVIII Concentrates Versus Standard Prophylaxis in Severe Haemophilia A

NCT05281185

Severe Hemophilia A Without Inhibitor

COMPLETEDPhase 3

Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII

NCT01992549

Severe Hemophilia A

View all related studies

Contacts

Sigurd Knaub, PhD

CONTACT

+41 554512141 Sigurd.Knaub@octapharma.com

Sponsors

Lead Sponsor

Octapharma

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 24, 2025Data synced to Clareo: April 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions